EraCal Therapeutics is focused on developing solutions for fighting obesity.

EraCal Therapeutics

EraCal Therapeutics  | 1,964 followers on LinkedIn. Towards an efficacious and well-tolerated appetite-suppressant using our innovative in-vivo screening platform | The biotech-company EraCal Therapeutics Ltd. is a spin-off of the University of Zurich and Harvard University, and develops first-in-class drugs to treat different diseases.

Attorney at Law, LL.M., Senior Associate at VISCHER AG

Pauline Pfirter

COO and Co-founder of Eracal Therapeutics

Simon Breitler

Senior Scientist bei EraCal Therapeutics

Stephanie Niklaus

We are thrilled to see our deal with Novo Nordisk has made the finals of the European Lifestars Awards - Celebrating Life Science Leaders . Looking forward to the ceremony in London next week. https://lnkd.in/dNeDbkCx

Proud to be selected in the Top 5 of Swiss biotech scale-ups 2024. https://lnkd.in/dV2-eDzE

Congratulations to Pauline Pfirter MLaw, LL.M. who was unanimously elected to the board of directors of EraCal Therapeutics. Welcome to the team Pauline, we are looking forward to shaping the future of EraCal Therapeutics together. https://www.eracal.ch/news

EraCal Therapeutics enters into a Collaboration and License Agreement with Novo Nordisk

ERAC

CH:ERACAL

EraCal Therapeutics